Pharmacological interventions for smoking cessation: an overview and network meta-analysis
- PMID: 23728690
- PMCID: PMC8406789
- DOI: 10.1002/14651858.CD009329.pub2
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Abstract
Background: Smoking is the leading preventable cause of illness and premature death worldwide. Some medications have been proven to help people to quit, with three licensed for this purpose in Europe and the USA: nicotine replacement therapy (NRT), bupropion, and varenicline. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries. Other therapies, including nortriptyline, have also been tested for effectiveness.
Objectives: How do NRT, bupropion and varenicline compare with placebo and with each other in achieving long-term abstinence (six months or longer)? How do the remaining treatments compare with placebo in achieving long-term abstinence? How do the risks of adverse and serious adverse events (SAEs) compare between the treatments, and are there instances where the harms may outweigh the benefits?
Methods: The overview is restricted to Cochrane reviews, all of which include randomised trials. Participants are usually adult smokers, but we exclude reviews of smoking cessation for pregnant women and in particular disease groups or specific settings. We cover nicotine replacement therapy (NRT), antidepressants (bupropion and nortriptyline), nicotine receptor partial agonists (varenicline and cytisine), anxiolytics, selective type 1 cannabinoid receptor antagonists (rimonabant), clonidine, lobeline, dianicline, mecamylamine, Nicobrevin, opioid antagonists, nicotine vaccines, and silver acetate. Our outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment. Our outcome for harms is the incidence of serious adverse events associated with each of the treatments. We searched the Cochrane Database of Systematic Reviews (CDSR) in The Cochrane Library, for any reviews with 'smoking' in the title, abstract or keyword fields. The last search was conducted in November 2012. We assessed methodological quality using a revised version of the AMSTAR scale. For NRT, bupropion and varenicline we conducted network meta-analyses, comparing each with the others and with placebo for benefit, and varenicline and bupropion for risks of serious adverse events.
Main results: We identified 12 treatment-specific reviews. The analyses covered 267 studies, involving 101,804 participants. Both NRT and bupropion were superior to placebo (odds ratios (OR) 1.84; 95% credible interval (CredI) 1.71 to 1.99, and 1.82; 95% CredI 1.60 to 2.06 respectively). Varenicline increased the odds of quitting compared with placebo (OR 2.88; 95% CredI 2.40 to 3.47). Head-to-head comparisons between bupropion and NRT showed equal efficacy (OR 0.99; 95% CredI 0.86 to 1.13). Varenicline was superior to single forms of NRT (OR 1.57; 95% CredI 1.29 to 1.91), and to bupropion (OR 1.59; 95% CredI 1.29 to 1.96). Varenicline was more effective than nicotine patch (OR 1.51; 95% CredI 1.22 to 1.87), than nicotine gum (OR 1.72; 95% CredI 1.38 to 2.13), and than 'other' NRT (inhaler, spray, tablets, lozenges; OR 1.42; 95% CredI 1.12 to 1.79), but was not more effective than combination NRT (OR 1.06; 95% CredI 0.75 to 1.48). Combination NRT also outperformed single formulations. The four categories of NRT performed similarly against each other, apart from 'other' NRT, which was marginally more effective than NRT gum (OR 1.21; 95% CredI 1.01 to 1.46). Cytisine (a nicotine receptor partial agonist) returned positive findings (risk ratio (RR) 3.98; 95% CI 2.01 to 7.87), without significant adverse events or SAEs. Across the 82 included and excluded bupropion trials, our estimate of six seizures in the bupropion arms versus none in the placebo arms was lower than the expected rate (1:1000), at about 1:1500. SAE meta-analysis of the bupropion studies demonstrated no excess of neuropsychiatric (RR 0.88; 95% CI 0.31 to 2.50) or cardiovascular events (RR 0.77; 95% CI 0.37 to 1.59). SAE meta-analysis of 14 varenicline trials found no difference between the varenicline and placebo arms (RR 1.06; 95% CI 0.72 to 1.55), and subgroup analyses detected no significant excess of neuropsychiatric events (RR 0.53; 95% CI 0.17 to 1.67), or of cardiac events (RR 1.26; 95% CI 0.62 to 2.56). Nortriptyline increased the chances of quitting (RR 2.03; 95% CI 1.48 to 2.78). Neither nortriptyline nor bupropion were shown to enhance the effect of NRT compared with NRT alone. Clonidine increased the chances of quitting (RR 1.63; 95% CI 1.22 to 2.18), but this was offset by a dose-dependent rise in adverse events. Mecamylamine in combination with NRT may increase the chances of quitting, but the current evidence is inconclusive. Other treatments failed to demonstrate a benefit compared with placebo. Nicotine vaccines are not yet licensed for use as an aid to smoking cessation or relapse prevention. Nicobrevin's UK license is now revoked, and the manufacturers of rimonabant, taranabant and dianicline are no longer supporting the development or testing of these treatments.
Authors' conclusions: NRT, bupropion, varenicline and cytisine have been shown to improve the chances of quitting. Combination NRT and varenicline are equally effective as quitting aids. Nortriptyline also improves the chances of quitting. On current evidence, none of the treatments appear to have an incidence of adverse events that would mitigate their use. Further research is warranted into the safety of varenicline and into cytisine's potential as an effective and affordable treatment, but not into the efficacy and safety of NRT.
Conflict of interest statement
Three authors of this overview (KC, RP, TL) have contributed to many of the included reviews.
Figures
![1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8406789/bin/nCD009329-AFig-FIG01.gif)
![2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8406789/bin/nCD009329-AFig-FIG02.gif)
![3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8406789/bin/nCD009329-AFig-FIG03.gif)
![4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8406789/bin/nCD009329-AFig-FIG04.gif)
Comment in
-
Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use.Evid Based Med. 2013 Dec;18(6):212-3. doi: 10.1136/eb-2013-101462. Epub 2013 Sep 12. Evid Based Med. 2013. PMID: 24030984 No abstract available.
-
Pharmacological treatments for smoking cessation.JAMA. 2014 Jan 8;311(2):193-4. doi: 10.1001/jama.2013.283787. JAMA. 2014. PMID: 24399558
Similar articles
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 May 09;(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. PMID: 22513936 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 May 5;5:CD006103. doi: 10.1002/14651858.CD006103.pub8. PMID: 27158893 Free PMC article. Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6. PMID: 21328282 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. PMID: 21154363 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. PMID: 18646137 Updated. Review.
Cited by
-
The Effect of Varenicline on Smoking Cessation in Hospitalized Patients: A Systematic Review and Meta-Analysis.Addict Health. 2024 May;16(2):122-129. doi: 10.34172/ahj.2024.1328. Epub 2024 May 1. Addict Health. 2024. PMID: 39051033 Free PMC article. Review.
-
The genetic landscape of substance use disorders.Mol Psychiatry. 2024 May 29. doi: 10.1038/s41380-024-02547-z. Online ahead of print. Mol Psychiatry. 2024. PMID: 38811691 Review.
-
The Differential Impact of Medical Therapy and Lifestyle Modification on Cardiovascular Health and Risk of Adverse Cardiovascular Events: A Narrative Review.Cureus. 2024 Apr 6;16(4):e57742. doi: 10.7759/cureus.57742. eCollection 2024 Apr. Cureus. 2024. PMID: 38716006 Free PMC article. Review.
-
Efficacy of the QuitSure App for Smoking Cessation in Adult Smokers: Cross-Sectional Web Survey.JMIR Hum Factors. 2024 May 6;11:e49519. doi: 10.2196/49519. JMIR Hum Factors. 2024. PMID: 38709553 Free PMC article.
-
Smoking cessation, harm reduction, and biomarkers protocols in the PhenX Toolkit: Tools for standardized data collection.Addict Neurosci. 2023 Sep;7:100081. doi: 10.1016/j.addicn.2023.100081. Epub 2023 Apr 8. Addict Neurosci. 2023. PMID: 38645895 Free PMC article.
References
References to included reviews
Antidepressants 2007
Anxiolytics 2010
Clonidine 2008
-
- Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000058.pub2] - DOI
Lobeline 2009
Mecamylamine 2011
Nicobrevin 2009
Nicotine receptor partial agonists 2012
Nicotine vaccines 2012
NRT 2012
Opioid antagonists 2009
Rimonabant 2011
References to excluded reviews
Adolescent cessation 2006
COPD patients 2001
Hospital patients 2012
Internet 2010
Pharmacists 2004
Pre‐operative patients 2010
Pregnancy 2009
Reduction vs abrupt 2010
Relapse prevention 2009
Schizophrenia 2010
Weight gain prevention 2009
Additional references
Atkins 2004
Benowitz 2008
-
- Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical Pharmacology and Therapeutics 2008;83(4):531‐41. - PubMed
Beyens 2008
-
- Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious Adverse Reactions of Bupropion for Smoking Cessation Analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Safety 2008;31:1017‐26. - PubMed
Boshier 2003
-
- Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. European Journal of Clinical Pharmacology 2003;59(10):767‐73. - PubMed
Brooks 1998
-
- Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998;7(4):434‐45.
Bucher 1997
-
- Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Chun‐Fai‐Chan 2005
-
- Chun‐Fai‐Chan B, Koren G, Fayez I, Kalra S, Voyer‐Lavigne S, Boshier A, Shakir S, Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192(3):932‐936. - PubMed
Coleman 2012
CONSORT 1996
-
- Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276(8):637‐9. - PubMed
Disease Control Priorities 2006
-
- Disease Control Priorities Project. Tobacco Addiction. http://www.dcp2.org/file/52/DCPP‐Tobacco.pdf (accessed 24th March 2013).
Dunner 1998
-
- Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained‐release in the treatment of depression. Journal of Clinical Psychiatry 1998;59:366‐73. - PubMed
Ebbert 2011
Eisenberg 2008a
Eisenberg 2008b
-
- Eisenberg MJ, Filion KB. Correction. Canadian Medical Association Journal 2008;179(8):802.
Eisenberg 2013
-
- Filion K, Eisenberg M. Personal communication 6th January 2013.
EMEA 2002
-
- European Agency for the Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products. Opinion following an article 36 referral. Bupropion hydrochloride. http://www.emea.eu.int/pdfs/human/referral/2761002en.pdf Accessed 29 April 2004.
Etter 2007
-
- Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta‐analysis. Addiction 2007;102:815‐22. - PubMed
Evans 2009
-
- Evans JR, Virgili G, Gordon I, Bunce C, Chakravarthy U, Desai P, et al. Interventions for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007650] - DOI
FDA 2011
-
- U. S. Food, Drug Administration. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm (accessed 19/1/2012) October 2011.
Fiore 1992
-
- Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA 1992;268:2687‐94. - PubMed
Fiore 2008
-
- Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville MD: US Department of Health and Human Services, 2008.
GlaxoSmithKline
-
- GlaxoSmithKline. Zyban(R) bupropion hydrochloride Sustained‐Release Tablets. Product Information. www.gsk.com/products/assets/us_zyban.pdf (accessed 15/11/2006).
GLS 2009
-
- Office for National Statistics. Smoking and drinking among adults, 2009. A report on the 2009 General Lifestyle Survey. ONS, 2011.
Gonzales 2006
-
- Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4ß2 nicotinic acetylcholine receptor partial agonist, vs sustained‐release bupropion and placebo for smoking cessation. JAMA 2006;296(1):47‐55. [clinicaltrials.gov ID: NCT00141206] - PubMed
Greenland 1998
-
- Greenland S, Satterfield MH, Lanes SF. A meta‐analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety 1998;18:297‐308. - PubMed
Gunnell 2009
Hajek 2013
Harrison‐Woolrych 2011
-
- Harrison‐Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Safety 2011;34(9):763‐72. - PubMed
Harrison‐Woolrych 2012
-
- Harrison‐Woolrych M, Maggo S, Tan M, Savage R, Ashton J. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Safety 2012;35(1):33‐43. - PubMed
Hubbard 2005
Hughes 2003
-
- Hughes JR, Keely JP, Niaura RS, Ossip‐Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5(1):13‐25. - PubMed
Jorenby 2006
-
- Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an α4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained‐release bupropion for smoking cessation. JAMA 2006;296(1):56‐63. [clinicaltrials.gov ID NCT00143364] - PubMed
Joseph 1996
-
- Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. New England Journal of Medicine 1996;335:1792‐8. - PubMed
Joseph 2003
-
- Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Progress in Cardiovascular Diseases 2003;45:429‐41. - PubMed
Kasliwal 2009
-
- Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription‐event monitoring study. Drug Safety 2009;32(6):499‐507. - PubMed
Kotlyar 2005
-
- Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology 2005;25:226‐9. - PubMed
Levine 2010
Lu 2004
-
- Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004;23(20):3105‐24. - PubMed
Lu 2006
-
- Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447‐59.
Lumley 2009
Mallett 2002
-
- Mallett S, Hopewell S, Clarke M. Grey literature in systematic reviews: The first 1000 Cochrane systematic reviews. Fourth symposium on systematic reviews: Pushing the boundaries. Oxford, 2002.
Meine 2005
-
- Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. American Journal of Cardiology 2005;95:976‐8. - PubMed
Meyer 2013
-
- Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013;108(1):203‐10. - PubMed
MHRA 2004
-
- Pharmacovigilance Information Unit, Medicines and Healthcare products Regulatory Agency (UK). Personal Communication 29 April 2004.
MHRA 2011
-
- Medicines and Healthcare products Regulatory Agency. MHRA UK Public Assessment Report|: Nicobrevin: withdrawn from UK market as risks outweigh benefits. http://www.mhra.gov.uk/home/groups/pl‐p/documents/websiteresources/con11... (accessed 20/11/2012) April 2011.
Mills 2010
Mills 2012
-
- Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high‐dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta‐analysis. Annals of Medicine 2012;44(6):588‐97. - PubMed
MMWR 2003
-
- Centers for Disease Control and Prevention. Cigarette smoking‐attributable morbidity ‐ United States 2000. MMWR Sep 2003. - PubMed
MMWR 2007
-
- Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2006. MMWR 2007;56:1157‐61. - PubMed
Myung 2012
-
- Myung S‐K, Ju W, Jung H‐S, Park C‐H, Oh S‐W, Seo HG, et al. Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta‐analysis. British Journal of Obstetrics and Gynaecology 2012;119(9):1029‐39. - PubMed
NHS 2008
-
- The Information Centre for Health and Social Care. Statistics on smoking: England. National Health Service, 2008.
Palmer 1992
-
- Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992;44:498‐529. - PubMed
Planer 2011
-
- Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Archives of Internal Medicine 2011;171(12):1055‐60. - PubMed
Plummer 2003 [Computer program]
-
- Plummer M. JAGS: a program for analysis of bayesian graphical models using gibbs sampling. Sourceforge ( https://sourceforge.net/projects/mcmc‐jags), 2003.
Plummer 2012 [Computer program]
-
- Plummer M. RJAGS: Bayesian graphical models using MCMC (http://CRAN.R‐project.org/package=rjags). Sourceforge (http://mcmc‐jags.sourceforge.net), 2012.
Pollak 2007
Prochaska 2012
RCP 2000
-
- Royal College of Physicians. Tobacco Addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. http://old.rcplondon.ac.uk/pubs/books/nicotine/index.htm (accessed 19th April 2011) 2000.
Rigotti 2010
-
- Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. Circulation 2010;121(2):221‐9. [clinicaltrials.gov ID: NCT00282984] - PMC - PubMed
Scherer 2007
SCOTH 1998
-
- Department of Health. Report of the Scientific Committee on Tobacco and Health. http://www.archive.official‐documents.co.uk/document/doh/tobacco/report.htm (accessed 19th April 2011) 1998.
Shea 2007
Shea 2011
-
- Shea B. Personal communication August 2011.
Singh 2011
Spiegelhalter 2002
-
- Spiegelhalter DJ, Best NG, Carlin BP, Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society: Series B: Statistical Methodlogy 2002;64(4):583‐616.
SRNT 2002
-
- SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research 2002;4(2):149‐59. - PubMed
Stapleton 1998
-
- Stapleton J. Cigarette smoking prevalence, cessation and relapse. Statistical Methods in Medical Research 1998;7(2):187‐203. - PubMed
Team 2012
-
- Team RC. A language and environment for statistical computing. http://www.R‐project.org (accessed 20/11/2012) 2012.
TGA 2004
-
- Adverse Drugs Reactions Unit, Therapeutic Goods Administration (Australia). Personal Communication 31 March 2004.
Thorlund 2013
TNWG 1994
-
- Transdermal Nicotine Working Group. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Archives of Internal Medicine 1994;154:989‐95. - PubMed
Tobacco Atlas 2010
-
- Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Atlas. The Tobacco Atlas. 3rd Edition. World Health Organization, 2010.
Tonstad 2010
-
- Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double‐blind, placebo‐controlled clinical trials of varenicline: a pooled analysis. Drug Safety 2010;33(4):289‐301. - PubMed
Tsoi 2010
Tønnesen 2012
UK Clinical Trials [Computer program]
-
- Current Controlled Trials. metaRegister of Controlled Trials (mRCT). Springer Science+Business Media, http://www.controlled‐trials.com/mrct/ (accessed 23rd May 2012).
US Clinical Trials [Computer program]
-
- United States National Institutes of Health. ClinicalTrials.gov. USNIH, http://clinicaltrials.gov/ct2/home (accessed 23rd May 2012).
USFDA 2009a
-
- Anon. Varenicline and bupropion. Reports of suicidality associated with used of varenicline (marketed as CHANTIX) and bupropion (marketed as Zyban and generics). FDA Drug Safety Newsletter 2009;2(1):1���4.
van der Meer 2009
van Valkenhoef 2012a
van Valkenhoef 2012b
-
- Valkenhoef G, Kuiper J. GeMTC: GeMTC network meta‐analysis. http://CRAN.R‐project.org/package=gemtc (accessed 20/11/2012) 2012.
Wallstrom 1999
-
- Wallstrom M, Sand L, Nilsson F, Hirsch JM. The long‐term effect of nicotine on the oral mucosa. Addiction 1999;94:417‐23. - PubMed
West 2006
-
- West R. Background smoking cessation rates in England. http://www.smokinginengland.info/Ref/paper2.pdf (accessed 19th April 2011) 2006.
WHO 2009
-
- World Health Organization. 17th expert committee on the selection and use of essential medicines. http://www.who.int/selection_medicines/committees/expert/17/en/index.html (accessed 19th April 2011) 2009.
WHO trials registry platform [Computer program]
-
- World Health Organization. Internation Clinical Trials Registry Platform Search Portal. WHO, http://apps.who.int/trialsearch/Default.aspx (accessed May 23rd 2012).
Williams 2007
-
- Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double‐blind study evaluating the long‐term safety of varenicline for smoking cessation. Current Medical Research and Opinion 2007;23(4):793‐801. [clinical trials.gov ID: 00143299] - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical